Vestar Inc. announced on Wednesday its first profitablequarter, based on sales of its flagship product, AmBisome.

AmBisome is an injectable, liposome-based form ofamphotericin B, a broad spectrum anti-infective to treatpotentially fatal systemic fungal infections.

For the third quarter ended Sept. 30, Vestar of San Dimas,Calif., had profits of 500,000, or 3 cents a share, on revenuesof $4.6 million. Product revenues were $4.2 million. For thecomparable 1990 quarter, Vestar had a net loss of $1.7million, or 26 cents a share, on revenues of $1.3 million.

Vestar shares (NASDAQ:VSTR) gained 75 cents, closing at $12,on Wednesday.

(c) 1997 American Health Consultants. All rights reserved.